Atara Biotherapeutics Inc. (ATRA) Upgraded to Hold at Zacks Investment Research
According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “
Several other brokerages also recently weighed in on ATRA. Goldman Sachs Group Inc. downgraded Atara Biotherapeutics from a neutral rating to a sell rating and dropped their price objective for the stock from $23.00 to $16.00 in a research report on Thursday. Citigroup Inc. upped their price objective on Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a sell rating in a research report on Friday, August 19th. Jefferies Group restated a buy rating and set a $25.00 price objective on shares of Atara Biotherapeutics in a research report on Sunday, July 10th. Canaccord Genuity restated a buy rating on shares of Atara Biotherapeutics in a research report on Tuesday, June 7th. Finally, JMP Securities restated a buy rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of Hold and an average target price of $26.14.
Atara Biotherapeutics (NASDAQ:ATRA) opened at 19.30 on Friday. The company’s market capitalization is $556.05 million. The company has a 50-day moving average price of $21.94 and a 200 day moving average price of $19.93. Atara Biotherapeutics has a 12 month low of $13.31 and a 12 month high of $49.94.
Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.05. On average, equities research analysts forecast that Atara Biotherapeutics will post ($2.85) EPS for the current fiscal year.
In other news, insider Christopher Haqq sold 1,346 shares of the firm’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $22.32, for a total transaction of $30,042.72. Following the completion of the transaction, the insider now directly owns 295,294 shares in the company, valued at $6,590,962.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Isaac E. Ciechanover sold 9,600 shares of the firm’s stock in a transaction dated Friday, July 8th. The stock was sold at an average price of $22.88, for a total value of $219,648.00. Following the transaction, the chief executive officer now owns 223,228 shares of the company’s stock, valued at $5,107,456.64. The disclosure for this sale can be found here. 16.10% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of ATRA. ProShare Advisors LLC increased its position in shares of Atara Biotherapeutics by 4.2% in the second quarter. ProShare Advisors LLC now owns 24,236 shares of the company’s stock worth $546,000 after buying an additional 980 shares during the period. JPMorgan Chase & Co. increased its position in shares of Atara Biotherapeutics by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 62,600 shares of the company’s stock worth $1,191,000 after buying an additional 1,900 shares during the period. BlackRock Group LTD increased its position in shares of Atara Biotherapeutics by 76.8% in the first quarter. BlackRock Group LTD now owns 5,400 shares of the company’s stock worth $103,000 after buying an additional 2,345 shares during the period. BlackRock Advisors LLC increased its position in shares of Atara Biotherapeutics by 30.2% in the second quarter. BlackRock Advisors LLC now owns 10,186 shares of the company’s stock worth $229,000 after buying an additional 2,361 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its position in shares of Atara Biotherapeutics by 23.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 16,200 shares of the company’s stock worth $365,000 after buying an additional 3,100 shares during the period. Institutional investors own 75.50% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.